Article
Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein.
Protein expression and purification - 1 Jan 2022
Gao Zhang-Zhao, Li Cui, Chen Gang, Yuan Jun-Jie, Zhou Ya-Qiong, Jiao Jing-Yu, Nie Lei, Qi Jian, Yang Yong, Chen Shu-Qing, Wang Hai-Bin
Abstract excerpt
The novel anti-PD-L1/TGFBR2-ECD fusion protein (BR102) comprises an anti-PD-L1 antibody (HS636) which is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment. In the expression of TGFBR2-ECD wild-type fused protein (BR102-WT), a 50 kDa clipped species was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.